Abstract
Hypertensive patients with diabetes have been reported to be considered at higher risk for the onset of cardiovascular diseases. Adiponectin, an anti-atherogenic adipocytokine, has been reported to improve insulin resistance. The aim of this study was to comparatively evaluate the effects of the angiotensin II receptor blockers, valsartan and telmisartan, on insulin resistance and adiponectin release in hypertensive patients with type 2 diabetes. Fifty-eight patients were randomly assigned to receive valsartan (n = 29) or telmisartan (n = 29). There was no difference in patient background in either group. Both agents reduced blood pressure to a similar degree, and homeostasis model assessment (HOMA-R) as a marker of insulin resistance was decreased in the valsartan group (3.78 ± 1.69 → 2.98 ± 1.50, p = 0.009) as well as in the telmisartan group (3.91 ± 1.65 → 3.39 ± 1.58, p = 0.046). However, adiponectin levels were significantly increased in the valsartan group (5.49 ± 2.12 → 5.81 ± 2.14 μg/ml, p = 0.028), but not in the telmisartan group (5.92 ± 2.19 → 5.87 ± 1.84 μg/ml, p = 0.781). These results suggest that both valsartan and telmisartan are appropriate anti-hypertensive agents providing improvement of insulin resistance; however, valsartan is the more beneficial agent due to the increase in adiponectin levels compared to telmisartan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nakamura T, Tsubono Y, Kameda-Takemura K, et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case–control study. Jpn Circ J. 2001;6511–17.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.
Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–6.
Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003 28;108:2034–40.
Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–8.
National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993–1002.
Islam MM, Horibe H, Kobayashi F. Current trend in prevalence of diabetes mellitus in Japan, 1964–1992. J Epidemiol. 1999;9:155–62.
Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003–10.
Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279–99.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
Satirapoj B, Yingwatanadej P, Chaichayanon S, et al. Effect of angiotensin II receptor blockers on insulin resistance in maintenance haemodialysis patients. Nephrology (Carlton). 2007;12:342–7.
Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:2313–8.
Top C, Cingözbay BY, Terekeci H, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res. 2002;30:15–20.
Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem. 2001;276:41245–54.
Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054–7.
Goossens GH, Jocken JW, Blaak EE, et al. Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension. 2007;49:542–7.
Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.
Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes. 2002;51:1699–707.
Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem. 2007;14:2918–24.
Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007;46:1331–6.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tomonaga, O., Iwamoto, Y. Comparative evaluation of angiotensin II receptor blockers on HOMA-R and adiponectin release in hypertensive patients with mild type 2 diabetes. Diabetol Int 1, 93–98 (2010). https://doi.org/10.1007/s13340-010-0012-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13340-010-0012-9